November 2023 Medical News Summary
Listen now
Description
Why Physicians Don’t Deprescribe Medicines; What to Know About Wegovy’s Rare but Serious Adverse Effects; What to Know About Zepbound, the Newest Antiobesity Drug
Related Content:
As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management Deciding When It’s Better to Deprescribe Medicines Than to Continue Them
More Episodes
Can AI/machine learning-driven digital phenotyping facilitate global personalized medicine? In this Q&A, Vikram Patel, MBBS, PhD, the Paul Farmer Professor and chair of the Department of Global Health and Social Medicine at Harvard Medical School, joins JAMA Editor in Chief Kirsten...
Published 05/03/24
An Explosion of Food Is Medicine Research Could Change Health Care; Blockbuster Obesity Drugs Have Potential New Uses
Related Content:
Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions? Produce Prescriptions Sound Good, but Data to...
Published 04/26/24
Published 04/26/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
